Phase 4
N=80
A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy
Muscle Weakness | Patient · Pain
Bottom Line
View on ClinicalTrials.gov: NCT02623361 ↗Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Numeric Pain Score — 7; 6 units on the numeric rating scale (0-10)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Peripheral Nerve Block (Drug); Sham Block (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Numeric Pain Score |
7; 6 | — |
| SECONDARY Leg Strength at Discharge From Ambulatory Center, Surgical Leg |
139; 41 | — |
| SECONDARY Patient Satisfaction |
10; 10 | — |
Summary
Patients undergoing arthroscopic hip surgery have been shown to have significant post-operative pain that may delay discharge, recovery, and early mobilisation. A pre-operative regional anesthesia technique, the fascia iliaca block may be an effective method for acute post-operative analgesia.
This is a prospective, randomized controlled study of the preoperative fascia iliaca block for patients undergoing hip arthroscopy.
The enrolled patients will be randomized to receive either a fascia iliaca block with the local anesthetic ropivacaine or to have a sham block. All patients will receive a general anesthetic for the hip arthroscopy.
Eligibility Criteria
Inclusion Criteria
- Age at least 18 years old
- American Society of Anesthesia physical classification I - III, scheduled for arthroscopic hip surgery
Exclusion Criteria
- Age younger than 18 years old
- Non-English speaking
- Contraindicated for regional nerve block (such as, but not limited to: coagulopathy, infection at site, allergy to local anesthetic)
- Preexisting neurologic deficits of operative limb
- Need for postoperative nerve function test
- Inability to consent due to cognitive dysfunction
- Chronic pain
- Patient refusal.
Data sourced from ClinicalTrials.gov (NCT02623361). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.